Beam launches early-stage study of allogeneic, base-edited CAR-T therapy R&D, Therapeutics Biotech Beam Therapeutics has dosed the first patient in a Phase I/II study of its base-edited CAR-T therapy in relapsed or refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Read more September 6, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/09/nucleotide.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-09-06 09:10:252023-09-06 09:29:15Beam launches early-stage study of allogeneic, base-edited CAR-T therapy
